# An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer

> **NCT06560112** · PHASE2 · RECRUITING · sponsor: **Akeso** · enrollment: 172 (estimated)

## Conditions studied

- Recurrent Ovarian Cancer

## Interventions

- **DRUG:** AK104
- **DRUG:** AK112
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT06560112
- **Lead sponsor:** Akeso
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-12
- **Primary completion:** 2026-05-01
- **Final completion:** 2027-05-01
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06560112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06560112, "An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06560112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*